FDA Approved: ENSPRYNG — Original Application (Genentech, Inc.)

View source ↗

Summary

The FDA approved ENSPRYNG (satralizumab) from Genentech as the original application for the treatment of neuromyelitis optica spectrum disorder (NMOSD) to reduc…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neuromyelitis Optica Spectrum Disorder

Drugs mentioned

• Enspryng (satralizumab)

Snippet

ORIG AP for ENSPRYNG (SATRALIZUMAB)